Who
Titus B. Ball
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, BeOne Medicines; Chief Accounting Officer, Carlisle Companies.
In numbers
- Trades disclosed
- 38
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $355K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 31 Dec 2016
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $47K132 at $355.86 | filing |
| 1 Sep 2026filed 3 Sep 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $47K132 at $355.86 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —31,213 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $13K49 at $256.39 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $31K120 at $257.53 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —31,213 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $13K49 at $256.39 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $31K120 at $257.53 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $27K100 at $271.06 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $9,79536 at $272.08 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $27K100 at $271.06 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $9,79536 at $272.08 | filing |
| 2 Sep 2025filed 4 Sep 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $40K122 at $326.76 | filing |
| 11 Jun 2025filed 12 Jun 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $35K134 at $258.36 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —29,601 at $0.00 | filing |
| 3 Sep 2024filed 5 Sep 2024 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $26K137 at $189.94 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,340 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —24,427 at $0.00 | filing |
| 2 Feb 2021filed 3 Feb 2021 | CSL Carlisle CompaniesBuilding Products & Timber | SEC FORM 4 Code A | —505 at $0.00 | filing |
| 2 Feb 2021filed 3 Feb 2021 | CSL Carlisle Companiesoption or derivative · Building Products & Timber | SEC FORM 4 Code A | —2,355 at $0.00 | filing |
News
Contrasting PainReform (NASDAQ:PRFX) & BeOne Medicines (NASDAQ:ONC)ONC · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Titus B. Ball; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.